BESPOKE CRC: The Impact of ctDNA-Guided Therapy in CRC

March 28, 2024

By John Strickler, MD
Aparna Raj Parikh, MD, MS

Opinion

Video

Focusing on the BESPOKE CRC study, John H. Strickler, MD, reviews recent updates presented at ASGO GI 2024 and discusses subset analyses from the trial.

EP: 1.Testing for MRD With ctDNA in Colorectal Cancer (CRC)

EP: 2.Platforms for Testing MRD in CRC

EP: 3.MRD Testing Practices in Colorectal Cancer

EP: 4.Patient Profile 1: A 50-Year-Old With Stage III Colorectal Cancer

EP: 5.Prospective Trial Data on MRD Testing in Early-Stage CRC

EP: 6.COSMOS-CRC-03: ctDNA and Recurrence in Colorectal Cancer

EP: 7.Patient Profile 2: A 39-Year-Old Woman with High-Risk Stage II CRC

EP: 8.DYNAMIC Trial: ctDNA Analysis Guiding Adjuvant Therapy in Early-Stage CRC

EP: 9.Colorectal Cancer: Key Updates from GALAXY At ASCO GI 2024

EP: 10.Rationale and Study Design of CIRCULATE-NORTH AMERICA in CRC

EP: 11.Initial Results from Phase 2 COBRA Study in Colorectal Cancer

EP: 12.Patient Profile 3: A 62-Year-Old Woman with Colon Cancer

EP: 13.The Study Design and Early Findings from the INTERCEPT Study in CRC

Now Viewing

EP: 14.BESPOKE CRC: The Impact of ctDNA-Guided Therapy in CRC

EP: 15.Future Perspectives on MRD Testing in Colorectal Cancer

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!